Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Longitudinal SARS-CoV-2 Antibody Response in Healthcare Workers: Benefit of Prior Infection and Heterologous Boosting on Anti-Spike IgG Immunity.

Created on 26 Oct 2026

Authors

Els Van Nedervelde, Ellen Vancutsem, Deborah De Geyter, Diederik De Cock, Rhea Buttiens, Thessa Laeremans, Joeri L Aerts, Sabine D Allard

Published in

Influenza and other respiratory viruses. Volume 20. Issue 1. Pages e70202.

Abstract

Different COVID-19 vaccine platforms elicit variable immune responses, influenced by prior infection and booster vaccination. We aimed to compare the humoral immune responses elicited by mRNA and adenoviral vector (Ad-vector) COVID-19 vaccines in hospital employees and to assess the possible impact of prior SARS-CoV-2 infection on these responses.
We performed a prospective observational cohort study by recruiting employees of the Universitair Ziekenhuis Brussel who were vaccinated with an mRNA or Ad-vector vaccine. We assessed anti-spike (S) IgG and neutralising capacity at 1, 6 and 12 months (post-mRNA booster). Anti-S and anti-NCP IgG were measured by chemiluminescent microparticle immunoassay, and neutralising capacity was assessed using Genscript's cPASS. Non-parametric group comparisons used the Mann-Whitney U test, complemented by multiple linear regression.
Following RVR, mRNA-vaccinated individuals (n = 380) exhibited higher anti-S IgG titres and neutralising capacity compared to those who received Ad-vector vaccines (n = 200). After the booster, anti-spike IgG remained higher in mRNA-vaccinated individuals than in Ad-vector recipients (q < 0.001); Ad-vector vaccinated individuals showed superior neutralising capacity. Natural SARS-CoV-2 infection prior to vaccination had varying impact on anti-S IgG and neutralising capacity, depending on vaccination type and time points.
Our findings underscore that both vaccine platforms and prior infections shape the magnitude and quality of the humoral immune response, highlighting the importance of considering priming strategy, booster design and hybrid immunity when optimising COVID-19 vaccination schedules for durable protection.

PMID:
41490379
Bibliographic data and abstract were imported from PubMed on 26 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 29
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement